Highlights from Gene Solutions Thailand participation at the Best of ASCO Bangkok 2024
On August 23-24, 2024, medical oncologists in Thailand gathered at the Best of ASCO Bangkok 2024 for two days of discussions and sharing about the latest advances in cancer care. Gene Solutions Thailand shared a notable exhibition on circulating tumor DNA (ctDNA) dynamics and Minimal Residual Disease (MRD) detection—two cutting-edge applications that have the potential to change the way oncologists monitor cancer, such as predicting treatment effectiveness or prognosing early signs of recurrence, giving patients a better chance at more personalized, timely treatments.
A particularly engaging moment occurred when discussions turned to the real-world implications of Next-Generation Sequencing (NGS) tests, especially concerning reimbursement opportunities for large-panel actionable mutations. This discussion underscored how enhanced access to genomic testing could fundamentally change patient outcomes.
One of the key highlights was the presentation of the K-DETEK study by MSc. Nguyen Van Thien Chi, our Research Associate. Featured earlier this year at the prestigious ASCO annual meeting, this study also captured the attention of attending oncologists, offering valuable insights into ctDNA application in Multi-Cancer Early Detection (MCED). This clinical validation has the potential to significantly improve cancer outcomes through earlier detection, earlier intervention, and treatment.
Throughout the event, oncologists shared their clinical experiences with ctDNA applications, providing us with valuable insights into its integration into everyday clinical practice. Many oncologists expressed a strong interest in prioritizing ctDNA monitoring (K-TRACK) for stage II colorectal cancer, inspired by the latest clinical data showcased at ASCO 2024.
Gene Solutions Thailand will continue to advance the field of cancer care, driven by the insights and discussions from these two days. We look forward to further collaboration and innovation as we work towards better outcomes for cancer patients.
